Maplight Therapeutics (NASDAQ:MPLT) Insider James Woodruff Lillie Sells 721 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 721 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $28.28, for a total transaction of $20,389.88. Following the sale, the insider directly owned 242,729 shares in the company, valued at $6,864,376.12. The trade was a 0.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total transaction of $713,564.36.
• On Tuesday, May 5th, James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total transaction of $312,879.00.
• On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total transaction of $441,795.96.

Maplight Therapeutics Price Performance

Shares of MPLT stock opened at $30.09 on Tuesday. The firm’s fifty day simple moving average is $23.27. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $33.28. The company has a market cap of $1.28 billion and a PE ratio of -0.76.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($1.42). As a group, analysts forecast that Maplight Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MPLT. Strs Ohio purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $53,000. Blue Owl Capital Holdings LP purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $5,745,000. Geode Capital Management LLC purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $6,835,000. Seven Grand Managers LLC purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $1,756,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $34,026,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MPLT. Needham & Company LLC began coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target on the stock. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target on the stock. TD Cowen began coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating on the stock. Wall Street Zen cut shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Weiss Ratings began coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.43.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.